Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis

被引：0
作者：
Naoki Iwamoto
Shuntaro Sato
Shota Kurushima
Toru Michitsuji
Shinya Nishihata
Momoko Okamoto
Yoshika Tsuji
Yushiro Endo
Toshimasa Shimizu
Remi Sumiyoshi
Takahisa Suzuki
Akitomo Okada
Tomohiro Koga
Shin-ya Kawashiri
Keita Fujikawa
Takashi Igawa
Toshiyuki Aramaki
Kunihiro Ichinose
Mami Tamai
Hideki Nakamura
Akinari Mizokami
Tomoki Origuchi
Yukitaka Ueki
Katsumi Eguchi
Atsushi Kawakami
机构：
[1] Nagasaki University Graduate School of Biomedical Sciences,Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences
[2] Nagasaki University Hospital,Clinical Research Center
[3] Sasebo City General Hospital,Department of Rheumatology
[4] Japanese Red Cross Nagasaki Genbaku Hospital,Department of Rheumatology
[5] Nagasaki University Graduate School of Biomedical Sciences,Center for Bioinformatics and Molecular Medicine
[6] Nagasaki University Graduate School of Biomedical Sciences,Departments of Community Medicine, Division of Advanced Preventive Medical Sciences
[7] Isahaya General Hospital,Department of Rheumatology, Japan Community Healthcare Organization
[8] Sasebo Chuo Hospital,Department of Rheumatology
[9] Nagasaki University Graduate School of Biomedical Sciences,Department of Physical Therapy
来源：
Arthritis Research & Therapy | / 23卷
关键词：
Rheumatoid arthritis; Tofacitinib; Baricitinib; Comparison; Molecular-targeted therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 342 条
  • [1] Aletaha D(2018)Diagnosis and management of rheumatoid arthritis: a review JAMA 320 1360-1372
  • [2] Smolen JS(2014)The use of biologic therapies in the treatment of rheumatoid arthritis Curr Pharm Biotechnol 15 542-548
  • [3] Wang D(2020)EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update Ann Rheum Dis 79 685-699
  • [4] Li Y(2016)Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases Nat Rev Rheumatol 12 25-36
  • [5] Liu Y(2012)Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis N Engl J Med 367 495-507
  • [6] Shi G(2014)Tofacitinib versus methotrexate in rheumatoid arthritis N Engl J Med 370 2377-2386
  • [7] Smolen JS(2013)Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial Ann Intern Med 159 253-261
  • [8] Landewe RBM(2013)Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study Arthritis Rheum 65 559-570
  • [9] Bijlsma JWJ(2012)Tofacitinib or adalimumab versus placebo in rheumatoid arthritis N Engl J Med 367 508-519
  • [10] Schwartz DM(2013)Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial Lancet 381 451-460
12345678910